Published in Cancer Immunol Immunother on July 19, 2008
Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg (2012) 1.60
From notochord formation to hereditary chordoma: the many roles of Brachyury. Biomed Res Int (2013) 1.12
Molecular characterization of putative chordoma cell lines. Sarcoma (2010) 1.09
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One (2012) 0.94
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res (2011) 0.90
The identification of transcription factors expressed in the notochord of Ciona intestinalis adds new potential players to the brachyury gene regulatory network. Dev Dyn (2011) 0.85
Theranostic impact of NG2/CSPG4 proteoglycan in cancer. Theranostics (2015) 0.82
Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines. J Neurosurg Spine (2014) 0.81
Novel targeted therapies in chordoma: an update. Ther Clin Risk Manag (2015) 0.81
The molecular aspects of chordoma. Neurosurg Rev (2015) 0.79
Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. Neuro Oncol (2014) 0.78
Recent advances in understanding and managing chordomas. F1000Res (2016) 0.75
Functional roles of CSPG4/NG2 in chondrosarcoma. Int J Exp Pathol (2016) 0.75
Nuances in the treatment of malignant tumors of the clival and petroclival region. Int Arch Otorhinolaryngol (2014) 0.75
α-methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas. Sci Rep (2016) 0.75
Intradural prepontine chordoma in an 11-year-old boy. A case report. Childs Nerv Syst (2015) 0.75
Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets. Surg Neurol Int (2013) 0.75
First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. Oncoimmunology (2017) 0.75
Sox9 is required for cartilage formation. Nat Genet (1999) 7.89
SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol (1997) 5.72
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem (2000) 3.20
Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol (2006) 2.65
Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer (2000) 2.40
Operative management of sacral chordoma. J Bone Joint Surg Am (2005) 2.12
Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol (2003) 1.94
Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein gene by Sox9. J Bone Miner Res (1999) 1.82
Transcription factors control invasion: AP-1 the first among equals. Oncogene (2006) 1.78
Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol (2004) 1.68
Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol (2008) 1.67
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res (2007) 1.65
Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res (2004) 1.63
Primary chondrosarcoma of long bones and limb girdles. Cancer (1998) 1.61
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.57
A molecular map of mesenchymal tumors. Genome Biol (2005) 1.52
Estimation of confidence in phylogeny: the complete-and-partial bootstrap technique. Mol Phylogenet Evol (1995) 1.49
Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am (2001) 1.48
Chondrosarcoma of bone. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am (1981) 1.46
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma (1989) 1.32
Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol (2004) 1.25
Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol (1998) 1.24
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A (1992) 1.24
The matrilins--adaptor proteins in the extracellular matrix. FEBS Lett (2005) 1.20
Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am (1989) 1.17
ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. Arthritis Rheum (2005) 1.10
Spinal chordomas. J Neurosurg (1979) 1.09
Chondrosarcoma. Clin Orthop Relat Res (1986) 1.07
Surgical Treatment of sacrococcygeal chordoma. J Surg Oncol (1997) 1.07
Chondroid chordoma--a variant of chordoma. A morphologic and immunohistochemical study. Am J Clin Pathol (1994) 1.06
Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol (1989) 1.06
Recent developments in cartilage research: matrix biology of the collagen II/IX/XI heterofibril network. Biochem Soc Trans (2002) 1.04
Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthritis Cartilage (2006) 0.99
Matrix gene expression analysis and cellular phenotyping in chordoma reveals focal differentiation pattern of neoplastic cells mimicking nucleus pulposus development. Am J Pathol (2001) 0.98
Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation, immortalization, and the tumor suppressors p16INK4a and p53. Mol Cell Biol (2004) 0.97
The role of extracellular factors in human metastatic chordoma cell growth in vitro. Spine (Phila Pa 1976) (2007) 0.96
Chondroid chordoma versus low-grade chondrosarcoma of the base of the skull: can immunohistochemistry resolve the controversy? J Neurooncol (1994) 0.91
Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol (2006) 0.87
Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol (2004) 0.85
Enhanced cell motility and invasion of chicken embryo fibroblasts in response to Jun over-expression. Int J Cancer (1999) 0.82
The effects of long term monolayer culture on the proteoglycan phenotype of a clonal population of mature human malignant chondrocytes. Connect Tissue Res (1991) 0.78
Bone sialoprotein and osteopontin distribution at the osteocartilaginous interface. Clin Orthop Relat Res (1996) 0.77
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Computational identification of microRNA targets. Dev Biol (2004) 6.84
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science (2002) 5.89
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev (2008) 5.34
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest (2010) 4.95
MicroRNA profiling of the murine hematopoietic system. Genome Biol (2005) 4.94
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 4.68
Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. Genome Biol (2013) 4.67
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol (2008) 3.34
Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med (2003) 3.30
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells (2007) 3.11
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
A hierarchical combination of factors shapes the genome-wide topography of yeast meiotic recombination initiation. Cell (2011) 3.08
Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med (2005) 3.04
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2012) 2.96
Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol (2004) 2.92
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One (2011) 2.80
Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis (2012) 2.72
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J (2005) 2.71
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis (2004) 2.68
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res (2005) 2.64
Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med (2007) 2.61
Childhood air pollutant exposure and carotid artery intima-media thickness in young adults. Circulation (2012) 2.51
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res (2007) 2.44
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res (2002) 2.41
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37
Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature (2010) 2.36
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer (2011) 2.34
miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell (2011) 2.33
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res (2005) 2.31
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A (2003) 2.23
The evolution of DNA regulatory regions for proteo-gamma bacteria by interspecies comparisons. Genome Res (2002) 2.22
BAC transgenesis in human embryonic stem cells as a novel tool to define the human neural lineage. Stem Cells (2009) 2.22
Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res (2002) 2.19
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol (2003) 2.18
A study of accuracy and precision in oligonucleotide arrays: extracting more signal at large concentrations. Bioinformatics (2003) 2.16
Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol (2005) 2.12
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med (2007) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Diagnosis and management of lipomatous tumors. J Surg Oncol (2008) 2.09
Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations. Ann Surg Oncol (2004) 2.09
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
Induction of sarcomas by mutant IDH2. Genes Dev (2013) 2.02
Serum transaminases are frequently elevated at time of diagnosis of idiopathic inflammatory myopathy and normalize with creatine kinase. J Clin Rheumatol (2014) 2.01
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer (2008) 1.99
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol (2013) 1.99
Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol (2003) 1.94
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol (2013) 1.94
Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins. Biochem J (2010) 1.94
TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol (2007) 1.94
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res (2004) 1.93
Patellar complications following distal femoral replacement after bone tumor resection. J Bone Joint Surg Am (2006) 1.90
Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res (2008) 1.89
Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov (2011) 1.85